AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure

Why It Matters

Heart failure affects millions and lacks curative options; successful trial data could introduce the first gene‑therapy that improves cardiac function and survival, reshaping the treatment landscape and creating significant market value.

Key Takeaways

• Enrollment completed for 173‑patient GenePHIT Phase 2 trial.
• AB‑1002 targets protein phosphatase‑1 via modified inhibitor‑1.
• Results expected first half of 2027, informing HFrEF therapy.
• Trial spans 46 sites across North America and Europe.
• AskBio, Bayer subsidiary, holds over 600 gene‑therapy patents.

Pulse Analysis

Heart failure affects roughly 64 million people worldwide and remains a leading cause of hospitalization and mortality despite advances in pharmacologic and device therapy. The disease’s high morbidity drives a relentless search for novel mechanisms that can improve cardiac contractility and survival. Gene‑therapy offers a one‑time, disease‑modifying approach, and AskBio’s AB‑1002 is engineered to deliver a modified inhibitor‑1 (I‑1c) that suppresses protein phosphatase‑1, a key regulator of calcium cycling in failing hearts. By restoring calcium handling, the therapy aims to boost ejection fraction and reduce symptomatic burden in patients with non‑ischemic HFrEF.

The GenePHIT study marks the most extensive enrollment to date for AB‑1002, randomizing 173 adults with NYHA Class III symptoms across 46 sites in the United States, Canada, and ten European countries. As a double‑blind, placebo‑controlled Phase 2 trial, it will assess cardiovascular‑related deaths, changes in NYHA class, left‑ventricular ejection fraction, and six‑minute walk distance. Completing enrollment ahead of schedule signals operational efficiency and positions AskBio to deliver interim safety data and the first efficacy readout in the first half of 2027, a milestone that could de‑risk the program for investors.

AskBio operates as a wholly owned subsidiary of Bayer AG, which reported 2025 sales of €45.6 billion (approximately $50 billion) and R&D spending of €5.8 billion (about $6.4 billion). The successful progression of AB‑1002 adds a high‑value asset to Bayer’s growing gene‑therapy portfolio, complementing its broader cardiovascular and neuromuscular pipelines. If the Phase 2 results confirm safety and efficacy, AB‑1002 could become one of the first gene‑based treatments for heart failure, opening a sizable market and reinforcing the strategic shift toward durable, single‑administration biologics in the biotech sector.